Study Evaluating the Effectiveness and Safety of XyloCore, a Low-Glucose Peritoneal Dialysis Solution, Compared to Standard Glucose Solutions in Adults with End-Stage Renal Disease
Led by Iperboreal Pharma Srl · Updated on 2026-03-24
170
Participants Needed
41
Research Sites
16 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to compare the effects of a new low glucose peritoneal dialysis solution called XyloCore against standard glucose-based solutions in patients with End-Stage Renal Disease ESRD who are undergoing Continuous Ambulatory Peritoneal Dialysis CAPD. The study is randomized, controlled, and open-label with blinded assessment of the main outcomes, conducted over a 6-month period. It includes patients already using common glucose peritoneal dialysis solutions and Extraneal for their long-dwell exchange.
Participants will be randomly assigned to receive either the experimental XyloCore solution or continue with their current glucose peritoneal dialysis solutions. XyloCore is provided in low, medium, or high strengths matched to the glucose concentration of the patients prior prescription, while the control group maintains their usual glucose-based solutions. Both groups will continue using Extraneal for the nocturnal long-dwell exchange. Dialysis prescriptions may be adjusted by investigators to meet a target dialysis adequacy measure KtV > 1.7 per week.
Throughout the study, participants will undergo regular assessments including measurement of dialysis adequacy total weekly KtVurea, blood tests such as HbA1c, cholesterol levels, hemoglobin, and insulin, as well as monitoring of kidney function, fluid removal, fatigue, and adverse events. The study includes follow-up visits for up to 6 months, with careful monitoring of safety and treatment effects. The trial is sponsored by Iperboreal Pharma Srl and uses centralized randomization with blinded evaluation of primary endpoints.
CONDITIONS
Brief Title
Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
Research Team
A
Arduino Arduini, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Major cardiovascular event within the last 3 months
Advanced cardiac failure (NYHA class 4)
Hypersensitivity to any study treatment components
Contraindications to prescribed peritoneal dialysis solutions
Medical history of clinically significant oxalate or lactate abnormalities
Other medical, neurological, or psychological conditions posing undue risk or interfering with study assessments as judged by investigator
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 24 weeks
Participants receive 1, 2, or 3 daily short-dwell exchanges of either the experimental XyloCore peritoneal dialysis solution or a glucose peritoneal dialysis solution. All participants continue to receive Extraneal for the nocturnal long-dwell exchange. The number and osmotic strength of diurnal exchanges may be modified as clinically required.
Regular visits at clinical centers as per treatment protocol
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating How Kidney Impairment Affects Ribupatide Levels in Adults With Severe Renal Disease or Healthy Participants Using Weekly Injections
Study of Blood Flow Sounds to Detect Complications in Vascular Access for Hemodialysis in Adults with End Stage Renal Disease
Phase 1 Study of Stem Cell Therapy to Improve Arteriovenous Fistulas for Hemodialysis in Adults with End Stage Renal Disease
Study of Expanded Dialysis Theranova Effects on Symptoms and Quality of Life in Adults on Hemodialysis Using LEVIL
Study of Blood Flow and Sound in Arteriovenous Fistulas for Patients with End-Stage Renal Disease
Using MRI and Ultrasound to Improve Hemodialysis Access Monitoring
Adapting the CAPABLE Program to Support Active Status and Improve Health for Adults Awaiting Kidney Transplant
Barts Health Cardio-Renal Registry for Patients With Kidney and Heart Disease
Evaluating the VIEWER Telemonitoring Platform to Reduce Hospital Visits in High Risk Stage 5 Chronic Kidney Disease Patients
Study Comparing Personalized Sodium Control With Standard Treatment in Hemodialysis for Kidney Failure
Combining CoQ10 Supplementation and High-Intensity Interval Training to Improve Mitochondrial Function and Physical Performance in Adults With Advanced Kidney Disease on Hemodialysis
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Rationale and design of ELIXIR, a randomized, controlled trial to evaluate efficacy and safety of XyloCore, a glucose-sparing solution for peritoneal dialysis.